483
RUBICON RESEARCH LIMITEDRUBICON RESEARCH LIMITED – FDA 483, Jan 27, 2023
Record Details
Rubicon Research Private Limited, a liquid oral dose finished drug manufacturer in Satara, India, was cited for significant deficiencies during an FDA inspection. The observations include inadequate laboratory controls for out-of-specification results, incomplete validation of critical manufacturing processes like bottle sealing, and plumbing system defects that pose a contamination risk. These issues indicate potential compromises to drug product quality and purity.
View Company Profile
ID · 493779a8-787c-429a-ad84-dea9aef52044
Other documents for RUBICON RESEARCH LIMITED
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.